somewordstoolate/Q2CRBench-3 huggingface dataset:
Guideline: 2020 EAN Dementia
Clinical question: Should patients with dementia (without previous stroke) and atrial fibrillation and indication for treatment with anti-coagulants be treated with anti-coagulants?
Population: Patients with dementia and atrial fibrillation and indication for treatment with anti-coagulants and no previous stroke or TCI
Intervention: Treatment with NOACs or warfarin
Comparator: No treatment with NOACs or warfarin
Outcome: Major hemorrhagic event
Importance: CRITICAL

Evidence assessment:
GRADE: Risk of bias: result: NONE
rationales: Risk of bias for this observational study was carried out using The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analyses. The study received maximum score on all items except one. There is no data on previous hemorrhagic events in the population, and hence no way to ascertain whether patients were not treated due to previous hemorrhagic events. This may introduce bias, since the reason for not anticoagulating may be affected by this. See Supplementary table S4 for further detail.
Inconsistency: result: NOT_APPLICABLE
rationales: Only one study, therefore not possible to assess
Indirectness: result: NOT_SERIOUS
rationales: Population (Stroke-free patients with atrial fibrillation), intervention (Treatment with warfarin) and outcome (Major hemorrhagic event, ischemic stroke, mortality) measures are deemed to be adequately similar to those in the PICO question. The summary data were provided by the author for the stroke-free population of the original cohort published in the original study (Subic et al 2018)
Imprecision: result: SERIOUS
rationales: Only data from one study. CI straddles 1.0. Optimal information size (OIS) was not met (control event rate 0.066; total events 144 observed; total events required 220-660 (RRR 20-30 %). Less than 400 events but more than 100. Wide confidence intervals.
Publication bias: result: NOT_SERIOUS
Other considerations: result: None
Study design: Observational Study
Certainty: VERY LOW
Risk: No treatment (comparator) mean (SD): 39c02ac0: 66/1000
Treatment with anticoagulants (intervention) mean (SD): 39c02ac0: 76/1000
Effect: Mean difference: 39c02ac0: 1.07 (0.82 - 1.39) (Hazard ratio (95 % confidence interval))
Guideline: 2020 EAN Dementia
Clinical question: Should patients with dementia (without previous stroke) and atrial fibrillation and indication for treatment with anti-coagulants be treated with anti-coagulants?
Population: Patients with dementia and atrial fibrillation and indication for treatment with anti-coagulants and no previous stroke or TCI
Intervention: Treatment with NOACs or warfarin
Comparator: No treatment with NOACs or warfarin
Outcome: Mortality
Importance: IMPORTANT

Evidence assessment:
GRADE: Risk of bias: result: NONE
rationales: Risk of bias for this observational study was carried out using The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analyses. The study received maximum score on all items except one. There is no data on previous hemorrhagic events in the population, and hence no way to ascertain whether patients were not treated due to previous hemorrhagic events. This may introduce bias, since the reason for not anticoagulating may be affected by this. See Supplementary table S4 for further detail.
Inconsistency: result: NOT_APPLICABLE
rationales: Only one study, therefore not possible to assess
Indirectness: result: NOT_SERIOUS
rationales: Population (Stroke-free patients with atrial fibrillation), intervention (Treatment with warfarin) and outcome (Major hemorrhagic event, ischemic stroke, mortality) measures are deemed to be adequately similar to those in the PICO question. The summary data were provided by the author for the stroke-free population of the original cohort published in the original study (Subic et al 2018)
Imprecision: result: SERIOUS
rationales: Only data from one study. CI straddles 1.0. Optimal information size (OIS) was met (control event rate 0.364; total events 630 observed; total events required 200-450 (RRR 20-30 %). Wide confidence intervals
Publication bias: result: NOT_SERIOUS
Other considerations: result: None
Study design: Observational Study
Certainty: VERY LOW
Risk: No treatment (comparator) mean (SD): 39c02ac0: 364/1000
Treatment with anticoagulants (intervention) mean (SD): 39c02ac0: 266/1000
Effect: Mean difference: 39c02ac0: 0.88 (0.77 - 1.01) (Hazard ratio (95 % confidence interval))
Guideline: 2020 EAN Dementia
Clinical question: Should patients with dementia (without previous stroke) and atrial fibrillation and indication for treatment with anti-coagulants be treated with anti-coagulants?
Population: Patients with dementia and atrial fibrillation and indication for treatment with anti-coagulants and no previous stroke or TCI
Intervention: Treatment with NOACs or warfarin
Comparator: No treatment with NOACs or warfarin
Outcome: Ischemic stroke
Importance: CRITICAL

Evidence assessment:
GRADE: Risk of bias: result: NONE
rationales: Risk of bias for this observational study was carried out using The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analyses. The study received maximum score on all items except one. There is no data on previous hemorrhagic events in the population, and hence no way to ascertain whether patients were not treated due to previous hemorrhagic events. This may introduce bias, since the reason for not anticoagulating may be affected by this. See Supplementary table S4 for further detail.
Inconsistency: result: NOT_APPLICABLE
rationales: Only one study, therefore not possible to assess
Indirectness: result: NOT_SERIOUS
rationales: Population (Stroke-free patients with atrial fibrillation), intervention (Treatment with warfarin) and outcome (Major hemorrhagic event, ischemic stroke, mortality) measures are deemed to be adequately similar to those in the PICO question. The summary data were provided by the author for the stroke-free population of the original cohort published in the original study (Subic et al 2018)
Imprecision: result: SERIOUS
rationales: Only data from one study. CI straddles 1.0. Optimal information size (OIS) was not met (control event rate 0.053; total events 95 observed; total events required 230-670 (RRR 20-30 %). Less than 100 events.
Publication bias: result: NOT_SERIOUS
Other considerations: result: None
Study design: Observational Study
Certainty: VERY LOW
Risk: No treatment (comparator) mean (SD): 39c02ac0: 53/1000
Treatment with anticoagulants (intervention) mean (SD): 39c02ac0: 42/1000
Effect: Mean difference: 39c02ac0: 0.74 (0.54 - 1.03) (Hazard ratio (95 % confidence interval))
Guideline: 2020 EAN Dementia
Clinical question: Should patients with dementia and agitation/aggressive behaviour be treated with atypical anti-psychotics compared to no pharmacological treatment?
Population: Patients with dementia and agitation/aggressive behavior 
Intervention: Treatment with aripripazole, zoleptil, olanzapine, quetiapin, risperidone or clozapine
Comparator:  No pharmacological treatment 
Outcome: Mortality
Importance: CRITICAL

Evidence assessment:
GRADE: Risk of bias: result: NOT_SERIOUS
Inconsistency: result: NOT_SERIOUS
Indirectness: result: NOT_SERIOUS
Imprecision: result: VERY_SERIOUS
rationales: Wide confidence intervals, few patients
Publication bias: result: NOT_SERIOUS
Other considerations: result: None
Study design: Randomized Controlled Trial
Certainty: LOW
Risk: No treatment (comparator) mean change score (SD) OR n/N: 50df60b4: 3.3% (placebo)
f5076959: 0/46
0643f463: 3/139
44c2f905: 0/31
d21566cc: 4/166
Treatment with typical antipsychotics (intervention) mean change score (SD) OR n/N: 50df60b4: 5.1% (quetiapine 200 mg/day), 7.3% (queti- apine 100 mg/day)
f5076959: 0/160
0643f463: 5/274
44c2f905: 1/30
d21566cc: 6/161
Effect: Mean difference in change score OR Relative risk (95 % CI): 50df60b4: RR 2.08 (95% CI: 0.61 - 7.16) (RR and percentage mortality includes 30-day follow-up. Nine Deaths occurred during the trial and 10 in the 30-day follow-up period)
f5076959: NA (Due to no events in one or both arms RR cannot be calculated)
0643f463: RR 0.85 (95% CI: 0.21 to 3.50)
44c2f905: NA (Due to no events in one or both arms RR cannot be calculated)
d21566cc: RR 1.53 (95% CI: 0.44 - 5.31)
Guideline: 2020 EAN Dementia
Clinical question: Should patients with dementia and agitation/aggressive behaviour be treated with atypical anti-psychotics compared to no pharmacological treatment?
Population: Patients with dementia and agitation/aggressive behavior 
Intervention: Treatment with aripripazole, zoleptil, olanzapine, quetiapin, risperidone or clozapine
Comparator:  No pharmacological treatment 
Outcome: Agitation/aggression
Importance: IMPORTANT

Evidence assessment:
GRADE: Risk of bias: result: NOT_SERIOUS
Inconsistency: result: SERIOUS
rationales: Point estimates vary widely, the direction of the effect is not consistent between the included studies
Indirectness: result: NOT_SERIOUS
Imprecision: result: SERIOUS
rationales: Wide confidence intervals, few patients
Publication bias: result: NOT_SERIOUS
Other considerations: result: None
Study design: Randomized Controlled Trial
Certainty: LOW
Risk: No treatment (comparator) mean change score (SD) OR n/N: 50df60b4: -2.5 (SD 0.9)
f5076959: -2.1 (SD 4.6)
c6e3bcaf: -0.1 (1.0)
44c2f905: -9.0 (16.5)
d21566cc: -3.1
Treatment with typical antipsychotics (intervention) mean change score (SD) OR n/N: 50df60b4: Intervention 1: - 2.5 (0.9); intervention 2: -1.8 (0.8)
f5076959: Intervention 1: -4.1 (3.7) Intervention 2: -3.9 (4.2) Intervention 3: -3.1 (4.1) 
c6e3bcaf: Intervention 1: -0.4 (2.1) Intervention 2: -0.3 (1.0) Intervention 3: -0.2 (1.1) 
44c2f905: -8.1 (12.7)
d21566cc: -7.5
Effect: Mean difference in change score OR Relative risk (95 % CI): 50df60b4: Intervention 1: 0 (95% CI: -0.25 to 0.25); Intervention 2 (95% CI 0.46 to 0.94)
f5076959: Intervention 1: -2 (95% CI -3.53 - 0.48); Intervention 2: -1.8, (95% CI -3.48 to 0.13); Intervention 3: -1 (95% CI 2.63 to -0.63,)
c6e3bcaf: Intervention 1: -0.3 (95% CI -0.70 to 0.10,); Intervention 2: -0.2 (95% CI -0.46 to 0.06); Intervnetion 3: - 0.1 (95% CI -0.38 to 0.18)
44c2f905: 0.9 (95% CI -6.58 to 8.38)
d21566cc: -4.4 (SD not reported for change scores)
Guideline: 2020 EAN Dementia
Clinical question: Should patients with dementia and agitation/aggressive behaviour be treated with atypical anti-psychotics compared to no pharmacological treatment?
Population: Patients with dementia and agitation/aggressive behavior 
Intervention: Treatment with aripripazole, zoleptil, olanzapine, quetiapin, risperidone or clozapine
Comparator:  No pharmacological treatment 
Outcome: Global cognitive function
Importance: IMPORTANT

Evidence assessment:
GRADE: Risk of bias: result: NOT_SERIOUS
Inconsistency: result: NOT_SERIOUS
Indirectness: result: NOT_SERIOUS
Imprecision: result: SERIOUS
rationales: Few patients
Publication bias: result: NOT_SERIOUS
Other considerations: result: None
Study design: Randomized Controlled Trial
Certainty: MODERATE
Risk: No treatment (comparator) mean change score (SD) OR n/N: baf84590: Not reported
f5076959: -0.3 (2.2) 
c6e3bcaf: -0.7 (2.7) 
44c2f905: 3.3 (17.4) 
Treatment with typical antipsychotics (intervention) mean change score (SD) OR n/N: baf84590: Not reported
f5076959: Intervention 1: -0.5 (3.3); Intervention 2: -1 (3.1); Intervention 3: -0.3 (2.2) 
c6e3bcaf: Intervention 1: -0.1 (3.7); Intervention 2: -0.8 (3.8); Intervention 3: -0.8 (3.2)
44c2f905: -11.3 (15.6)
Effect: Mean difference in change score OR Relative risk (95 % CI): baf84590: -0.1 (-2.9 to 2.6)
f5076959: Intervention 1: -0.2, (95% CI -0.92 to 1.32); Intervention 2: -0.7 (95% CI -0.39 to 1.79); Intervention 3: 0 (95% CI -0.88 to 0.88)
c6e3bcaf: Intervention 1: 0.6 (95% CI -0.21 to 1.41); Intervention 2: -0.1 (95% CI -0.93 to 0.73); Intervention 3: -0.1 (95% CI -0.88 to 0.68)
44c2f905: −15.4 (−27.0 to −3.8)
Guideline: 2020 EAN Dementia
Clinical question: Should patients with dementia and agitation/aggressive behaviour be treated with atypical anti-psychotics compared to no pharmacological treatment?
Population: Patients with dementia and agitation/aggressive behavior 
Intervention: Treatment with aripripazole, zoleptil, olanzapine, quetiapin, risperidone or clozapine
Comparator:  No pharmacological treatment 
Outcome: SAEs
Importance: CRITICAL

Evidence assessment:
GRADE: Risk of bias: result: NOT_SERIOUS
Inconsistency: result: NOT_SERIOUS
Indirectness: result: NOT_SERIOUS
Imprecision: result: VERY_SERIOUS
rationales: Wide confidence intervals, few patients
Publication bias: result: NOT_SERIOUS
Other considerations: result: None
Study design: Randomized Controlled Trial
Certainty: LOW
Risk: No treatment (comparator) mean change score (SD) OR n/N: 50df60b4: 9/83
baf84590: 2/18
0643f463: 19/123
44c2f905: 1/30 
d21566cc: 15/155
Treatment with typical antipsychotics (intervention) mean change score (SD) OR n/N: 50df60b4: 21/220
baf84590: 2/18
0643f463: 40/239
44c2f905: 1/30
d21566cc: 28/139
Effect: Mean difference  in change score OR Relative risk (95 % CI): 50df60b4: RR: 0.89 (95% CI: 0.42 to 1.87)
baf84590: RR: 1 (95% CI: 0.16 to 6.42)
0643f463: RR: 1.07 (95% CI: 0.65 to 1.78)
44c2f905: RR: 1 (95% CI: 0.07 to 15.28)
d21566cc: RR: 1.9 (95% CI: 1.05 to 3.43)
Guideline: 2020 EAN Dementia
Clinical question: Should patients with dementia and agitation/aggressive behaviour be treated with atypical anti-psychotics compared to haloperidol?
Population: Patients with dementia and agitation/aggressive behavior 
Intervention: Treatment with aripripazole, zoleptil, olanzapine, quetiapin, risperidone or clozapine
Comparator: Haloperidol
Outcome: Mortality
Importance: CRITICAL

Evidence assessment:
GRADE: Risk of bias: result: NOT_SERIOUS
Inconsistency: result: NOT_SERIOUS
Indirectness: result: NOT_SERIOUS
Imprecision: result: VERY_SERIOUS
rationales: Low number of patients, no events in any studies
Publication bias: result: NOT_SERIOUS
Other considerations: result: None
Study design: Randomized Controlled Trial
Certainty: LOW
Risk: Treatment with haloperidol (comparator) mean change score OR n/N: 2271541c: 0/60
793447a7: 0/28
8c317dba: 0/29
Treatment with typical antipsychotics (intervention) mean change score (SD) OR n/N: 2271541c: 0/60
793447a7: 0/30
8c317dba: 0/29
Effect: Mean difference  in change score OR Relative risk (95 % CI): 2271541c: NA (Due to no events in one or both arms RR cannot be calculated)
793447a7: NA (Due to no events in one or both arms RR cannot be calculated)
8c317dba: NA (Due to no events in one or both arms RR cannot be calculated)
Guideline: 2020 EAN Dementia
Clinical question: Should patients with dementia and agitation/aggressive behaviour be treated with atypical anti-psychotics compared to haloperidol?
Population: Patients with dementia and agitation/aggressive behavior 
Intervention: Treatment with aripripazole, zoleptil, olanzapine, quetiapin, risperidone or clozapine
Comparator: Haloperidol
Outcome: Agitation/aggression
Importance: IMPORTANT

Evidence assessment:
GRADE: Risk of bias: result: NOT_SERIOUS
Inconsistency: result: SERIOUS
rationales: Point estimates vary widely
Indirectness: result: NOT_SERIOUS
Imprecision: result: SERIOUS
rationales: Few patients
Publication bias: result: NOT_SERIOUS
Other considerations: result: None
Study design: Randomized Controlled Trial
Certainty: LOW
Risk: Treatment with haloperidol (comparator) mean change score OR n/N: 2271541c: 4.9
793447a7: -16.6
8c317dba: -10
64979d7f: -3.6
Treatment with atypical antipsychotics (intervention) mean change score (SD) OR n/N: 2271541c: -11.2
793447a7: -10.1(-18.6 to - 1.5)
8c317dba: -8.1
64979d7f: -8.3
Effect: Mean difference  in change score OR Relative risk (95 % CI): 2271541c: -6.3 (SD or other measure of variance not reported. Scores are mean change scores)
793447a7: 6.5
8c317dba: 1.9 (SD or other measure of variance not reported. Scores are mean change scores)
64979d7f: -4.7 (SD or other measure of variance not reported. Scores are mean change scores)
Guideline: 2020 EAN Dementia
Clinical question: Should patients with dementia and agitation/aggressive behaviour be treated with atypical anti-psychotics compared to haloperidol?
Population: Patients with dementia and agitation/aggressive behavior 
Intervention: Treatment with aripripazole, zoleptil, olanzapine, quetiapin, risperidone or clozapine
Comparator: Haloperidol
Outcome: Global cognitive function
Importance: IMPORTANT

Evidence assessment:
GRADE: Risk of bias: result: NOT_SERIOUS
Inconsistency: result: SERIOUS
rationales: Point estimates vary widely 
Indirectness: result: NOT_SERIOUS
Imprecision: result: VERY_SERIOUS
rationales: Low number of patients
Publication bias: result: NOT_SERIOUS
Other considerations: result: None
Study design: Randomized Controlled Trial
Certainty: VERY LOW
Risk: Treatment with haloperidol (comparator) mean change score OR n/N: 793447a7: -0.13
8c317dba: -0.15
Treatment with atypical antipsychotics (intervention) mean change score (SD) OR n/N: 793447a7: 0.53
8c317dba: -0.42
Effect: Mean difference  in change score OR Relative risk (95 % CI): 793447a7: 0.66 (SD not reported. Values are for change from baseline)
8c317dba: -0.27 (SD not reported. Values are for change from baseline)
Guideline: 2020 EAN Dementia
Clinical question: Should patients with dementia and agitation/aggressive behaviour be treated with atypical anti-psychotics compared to haloperidol?
Population: Patients with dementia and agitation/aggressive behavior 
Intervention: Treatment with aripripazole, zoleptil, olanzapine, quetiapin, risperidone or clozapine
Comparator: Haloperidol
Outcome: Serious adverse events
Importance: CRITICAL

Evidence assessment:
GRADE: Risk of bias: result: NOT_SERIOUS
Inconsistency: result: NOT_APPLICABLE
rationales: Due to no events in one or both arms RR cannot be calculated
Indirectness: result: NOT_SERIOUS
Imprecision: result: VERY_SERIOUS
rationales: Only data from one study. Low number of patients, no events in the study
Publication bias: result: NOT_SERIOUS
Other considerations: result: None
Study design: Randomized Controlled Trial
Certainty: VERY LOW
Risk: Treatment with haloperidol (comparator) mean change score OR n/N: 2271541c: 0/60
Treatment with atypical antipsychotics (intervention) mean change score (SD) OR n/N: 2271541c: 0/60
Effect: Mean difference  in change score OR Relative risk (95 % CI): 2271541c: N/A (Due to no events in one or both arms RR cannot be calculated)
Guideline: 2020 EAN Dementia
Clinical question: Should treatment with antipsychotics be routinely discontinued?
Population: Patients dementia who are currently being treated with anti-psychotics
Intervention: Discontinuation of antipsychotics
Comparator: Continuation of treatment
Outcome: Mortality
Importance: CRITICAL

Evidence assessment:
GRADE: Risk of bias: result: NOT_SERIOUS
Inconsistency: result: NOT_SERIOUS
Indirectness: result: NOT_SERIOUS
Imprecision: result: VERY_SERIOUS
rationales: Wide confidence intervals, Low number of patients, few events in any studies
Publication bias: result: NOT_SERIOUS
Other considerations: result: None
Study design: Randomized Controlled Trial
Certainty: LOW
Risk: Continuation of treatment with anti-psychotics (Comparator) mean (SD) Or n/N: 39351825: 1/27
7e48dccc:  0/14
8f835918: 1/69
c57b6880: 3/51
135b5748: 10/72
aead9e3a: 0/10
Discontinuation of treatment with anti-psychotics (intervention) mean change score (SD) OR n/N: 39351825: 3/24
7e48dccc: 0/22
8f835918: 1/39
c57b6880: 3/43
135b5748: 2/83
aead9e3a: 0/10
Effect: Mean difference (95 % CI) OR Relative risk (95 % CI): 39351825: 3.11 (0.34 - 28.09)
7e48dccc: NA (Due to no events in one or both arms RR cannot be calculated)
8f835918: 1.75
c57b6880: 1.17 (0.25 - 5.54)
135b5748: 0.19 (0.046 to 0.90)
aead9e3a: NA (Due to no events in one or both arms RR cannot be calculated)
Guideline: 2020 EAN Dementia
Clinical question: Should treatment with antipsychotics be routinely discontinued?
Population: Patients dementia who are currently being treated with anti-psychotics
Intervention: Discontinuation of antipsychotics
Comparator: Continuation of treatment
Outcome: Neuropsychiatric symptoms
Importance: IMPORTANT

Evidence assessment:
GRADE: Risk of bias: result: NOT_SERIOUS
Inconsistency: result: NOT_SERIOUS
Indirectness: result: NOT_SERIOUS
Imprecision: result: VERY_SERIOUS
rationales: Wide confidence intervals, Low number of patients, low number of events
Publication bias: result: NOT_SERIOUS
Other considerations: result: None
Study design: Randomized Controlled Trial
Certainty: LOW
Risk: Continuation of treatment with anti-psychotics (Comparator) mean (SD) Or n/N: 39351825: -1.79 (4.9)
1ad70ba1: Results only reported in a figure. No measure of variance.
c57b6880: 0.2 (12) 
4f4e0f75: 3.52 (20.78) 
aead9e3a: N/A
Discontinuation of treatment with anti-psychotics (intervention) mean change score (SD) OR n/N: 39351825: -0.19 (5.3)
1ad70ba1: N/A
c57b6880: -1.3 (9.4)
4f4e0f75:  2.04 (18.2)
aead9e3a: N/A
Effect: Mean difference (95 % CI) OR Relative risk (95 % CI): 39351825: 1.6 (95% CI   -1.16 to 4.36)
1ad70ba1: N/A
c57b6880: -1.5 (95% CI -6.34 to -3.34)
4f4e0f75: -1.48 (-8.70 to 5.74)
aead9e3a: 1.94; (1.09 to -3.45) (Hazard ratios for the first 16 weeks of phase B. Hazard ratio for placebo compared to antipsychotics)
Guideline: 2020 EAN Dementia
Clinical question: Should treatment with antipsychotics be routinely discontinued?
Population: Patients dementia who are currently being treated with anti-psychotics
Intervention: Discontinuation of antipsychotics
Comparator: Continuation of treatment
Outcome: Global cognitive function
Importance: IMPORTANT

Evidence assessment:
GRADE: Risk of bias: result: NOT_SERIOUS
Inconsistency: result: NOT_APPLICABLE
rationales: Only one study
Indirectness: result: NOT_SERIOUS
Imprecision: result: VERY_SERIOUS
rationales: Wide confidence intervals, Low number of patients, Only data from one study
Publication bias: result: NOT_SERIOUS
Other considerations: result: None
Study design: Randomized Controlled Trial
Certainty: VERY LOW
Risk: Continuation of treatment with anti-psychotics (Comparator) mean (SD) Or n/N: 4f4e0f75: -16.5 (23.1)
Discontinuation of treatment with anti-psychotics (intervention) mean change score (SD) OR n/N: 4f4e0f75: -8.5 (13.4)
Effect: Mean difference (95 % CI) OR Relative risk (95 % CI): 4f4e0f75: 8 (2.20 - 13.80) (Calculated)
Guideline: 2020 EAN Dementia
Clinical question: Should treatment with antipsychotics be routinely discontinued?
Population: Patients dementia who are currently being treated with anti-psychotics
Intervention: Discontinuation of antipsychotics
Comparator: Continuation of treatment
Outcome: Serious adverse events
Importance: CRITICAL

Evidence assessment:
GRADE: Risk of bias: result: NOT_SERIOUS
Inconsistency: result: NOT_APPLICABLE
rationales: Only one study
Indirectness: result: NOT_SERIOUS
Imprecision: result: VERY_SERIOUS
rationales: Wide confidence intervals, Low number of patients, Only data from one study, low number of events
Publication bias: result: NOT_SERIOUS
Other considerations: result: None
Study design: Randomized Controlled Trial
Certainty: VERY LOW
Risk: Continuation of treatment with anti-psychotics (Comparator) mean (SD) Or n/N: 8f835918: 5/65
Discontinuation of treatment with anti-psychotics (intervention) mean change score (SD) OR n/N: 8f835918: 8/32
Effect: Mean difference (95 % CI) OR Relative risk (95 % CI): 8f835918: 2.80 (0.98 - 7.98)